Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Envudeucitinib · ESK-001, FTP-637

Small molecule · developed by Alumis

Phase 3 Most advanced trial

ALMS Developer

4 Registered trials

What is Envudeucitinib?

Envudeucitinib (ESK-001) is an investigational agent studied in plaque psoriasis, including in a randomized treatment withdrawal period.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: ESK-001, FTP-637, Experimental drug: ESK-001
Drug type: Small molecule
Therapy area: Dermatology
Developer: Alumis Inc (ALMS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: KD2MDJ4GAB

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06846541	Phase 3	Plaque Psoriasis	Active not recruiting	ALMS
NCT06586112	Phase 3	Plaque Psoriasis	Completed	ALMS
NCT05600036	Phase 2	Plaque Psoriasis	Completed	ALMS
NCT05431634	Phase 1	Safety and Tolerability	Completed	ALMS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Moderate PsoriasisPsoriasisPsoriasis (PsO)Severe PsoriasisPlaque PsoriasisSafety and Tolerability

More from Alumis

A-005 Phase 1

Sources

ClinicalTrials.gov NCT06846541

Updated Oct 11, 2026. Something wrong or missing? Report it on the ALMS page.

Follow ALMS, the company behind Envudeucitinib

See ALMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALMS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z